MARK2 and neoplasm: In neostriatal neurons, GRM1 activation by binding of a group I mGluR agonist results in activation of casein kinase 1 (CK1), a highly conserved serine-threonine kinase which was recently implicated as a tumor suppressor in melanoma [52], [53].